Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30973010 | 1.00 | BACE1 (0.35) | BACE1GPR35POLBTHRBNPSR1 | |
| SCHEMBL29725911 | 0.91 | BACE1 (0.34) | BACE1GPR35POLBTHRBNPSR1 | |
| SCHEMBL29725964 | 0.91 | BACE1 (0.34) | BACE1GPR35POLBTHRBNPSR1 | |
| SCHEMBL25819422 | 0.91 | BACE1 (0.34) | BACE1GPR35POLBTHRBNPSR1 | |
| SCHEMBL28957391 | 0.91 | BACE1 (0.34) | BACE1GPR35POLBTHRBNPSR1 | |
| SCHEMBL23259944 | 0.91 | BACE1 (0.34) | BACE1GPR35POLBTHRBNPSR1 | |
| SCHEMBL29725940 | 0.89 | GPR35 (0.36) | BACE1GPR35POLBTHRB | |
| SCHEMBL28871842 | 0.89 | GPR35 (0.36) | BACE1GPR35POLBTHRB | |
| SCHEMBL24555571 | 0.89 | GPR35 (0.36) | BACE1GPR35POLBTHRB | |
| SCHEMBL23256376 | 0.88 | BACE1 (0.35) | BACE1GPR35POLBTHRBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240279214-A1 | ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279214-A1 | ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF | ITGB7, ITGB4, ITGA4 | BACE1 437/4885GPR35 670/4885POLB 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.